[
  {
    "ts": null,
    "headline": "Solventum price target raised to $73 from $60 at Morgan Stanley",
    "summary": "Morgan Stanley raised the firm’s price target on Solventum (SOLV) to $73 from $60 and keeps an Equal Weight rating on the shares. Solventum, which “had a clean 3Q print,” seems to be navigating a difficult MedTech backdrop relatively well, especially within the core MedSurg business, the analyst tells investors in a post-earnings note. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >>",
    "url": "https://finnhub.io/api/news?id=2dde1ea2927e722ef5fbe702fd286137176d275d271b1aba5fc3430b7c2bafa5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731412282,
      "headline": "Solventum price target raised to $73 from $60 at Morgan Stanley",
      "id": 131310885,
      "image": "https://media.zenfs.com/en/tipranks_452/ea7d93919fc9da6c2816cb36023ae54f",
      "related": "SOLV",
      "source": "Yahoo",
      "summary": "Morgan Stanley raised the firm’s price target on Solventum (SOLV) to $73 from $60 and keeps an Equal Weight rating on the shares. Solventum, which “had a clean 3Q print,” seems to be navigating a difficult MedTech backdrop relatively well, especially within the core MedSurg business, the analyst tells investors in a post-earnings note. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >>",
      "url": "https://finnhub.io/api/news?id=2dde1ea2927e722ef5fbe702fd286137176d275d271b1aba5fc3430b7c2bafa5"
    }
  }
]